ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Show more...
執行長
員工
35
國家
US
ISIN
US04522R3093
WKN
000A2JN62
上市
0 Comments
分享你的想法
FAQ
ASLAN Pharmaceuticals 今天的股價是多少?▼
ASLN 目前價格為 $0.6 USD,過去 24 小時下跌了 -14.27%。在圖表上更密切關注 ASLAN Pharmaceuticals 股票的表現。